Edition:
United Kingdom

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

8.32USD
22 Jul 2019
Change (% chg)

$0.05 (+0.60%)
Prev Close
$8.27
Open
$8.21
Day's High
$8.53
Day's Low
$7.68
Volume
55,296
Avg. Vol
55,402
52-wk High
$11.44
52-wk Low
$6.20

Latest Key Developments (Source: Significant Developments)

Catalyst Biosciences Says Co Meets Primary Endpoint In Phase 2 Trial Of Subcutaneous MarzAA
Monday, 8 Jul 2019 

July 8 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES MEETS THE PRIMARY ENDPOINT OF REDUCTION IN ANNUALIZED BLEEDING RATE IN THE PHASE 2 TRIAL OF SUBCUTANEOUS MARZEPTACOG ALFA (ACTIVATED) IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS.SUBCUTANEOUS MARZAA (FVIIA) PROPHYLAXIS REDUCED ANNUALIZED BLEEDING RATE BY MORE THAN 90% COMPARED WITH PRETREATMENT.  Full Article

Mangrove Partners Reports 5.0% Passive Stake In Catalyst Biosciences As Of May 10
Tuesday, 14 May 2019 

May 14 (Reuters) - Mangrove Partners::MANGROVE PARTNERS REPORTS 5.0% PASSIVE STAKE IN CATALYST BIOSCIENCES INC AS OF MAY 10 - SEC FILING.  Full Article

Catalyst Biosciences Reports Q1 Loss Per Share $1.26
Thursday, 2 May 2019 

May 2 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES REPORTS FIRST QUARTER 2019 OPERATING & FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q1 LOSS PER SHARE $1.26.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2019 WERE $105.3 MILLION.  Full Article

Catalyst Biosciences Provides Corporate Update
Thursday, 1 Mar 2018 

March 1 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CATALYST BIOSCIENCES - ‍CASH BALANCE OF OVER $135 MILLION AFTER FEB FOLLOW-ON FINANCING ALLOWS FOR INDEPENDENT DEVELOPMENT OF LEAD PROGRAMS​.CATALYST BIOSCIENCES INC - ‍COMPANY HAS NO OUTSTANDING NOTES OR DEBT​.CATALYST BIOSCIENCES INC - ‍INTEREST AND OTHER INCOME FOR QUARTER WAS $0.1 MILLION, VERSUS $1.5 MILLION FOR PRIOR YEAR PERIOD​.  Full Article

Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D.CATALYST BIOSCIENCES INC - PLAN TO INITIATE A PHASE 2B STUDY OF CB 2679D IN INDIVIDUALS WITH SEVERE HEMOPHILIA B IN Q3 OF 2018.  Full Article

Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.94 MILLION COMMON SHARES PRICED AT $34.00PER SHARE.  Full Article

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES - ‍ANTICIPATES USING OFFERING PROCEEDS FOR PURPOSES INCLUDING CLINICAL & MANUFACTURING ACTIVITIES FOR CB 2679D, MARZEPTACOG ALFA​.  Full Article

RTW Investments Reports A 5.71 Percent Passive Stake In Catalyst Biosciences
Monday, 5 Feb 2018 

Feb 5 (Reuters) - Catalyst Biosciences Inc ::RTW INVESTMENTS, LP REPORTS A 5.71 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF JAN 26, 2018 .  Full Article

Catalyst Biosciences Files For Mixed Shelf Of Up To $150 Mln
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING.  Full Article

Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences
Wednesday, 27 Dec 2017 

Dec 28 (Reuters) - Catalyst Biosciences Inc ::NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING.  Full Article